Takara BioFRA:TF2 50 Return-on-Tangible-Equity is 0.10% as of Mar. 2026, which is 98% below its 10-year median of 5.81. GuruFocus rates FRA:TF2 with a GF Score™ of 50/100 and a GF Value™ of €4.47. The stock has 6 warning signs investors should review. Among 1,195 Biotechnology companies, Takara Bio ranks better than 69.29% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Takara Bio's annualized net income for the quarter that ended in Mar. 2026 was €0.4 Mil. Takara Bio's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €425.9 Mil. Therefore, Takara Bio's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 0.10%.
The historical rank and industry rank for Takara Bio's Return-on-Tangible-Equity or its related term are showing as below:
FRA:TF2'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -11.27 Med: 5.81 Max: 26.2
Current: -11.27
During the past 13 years, Takara Bio's highest Return-on-Tangible-Equity was 26.20%. The lowest was -11.27%. And the median was 5.81%.
FRA:TF2's Return-on-Tangible-Equity is ranked better than 69.29% of 1195
companies
in the Biotechnology industry
Industry Median: -42.21
vs FRA:TF2: -11.27
Takara Bio (FRA:TF2) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Takara Bio Return-on-Tangible-Equity Related Terms
Takara Bio Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Takara Bio's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TF2 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Takara Bio's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takara Bio Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Takara Bio's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Takara Bio's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.10% mean?
Takara Bio (FRA:TF2) has a Return-on-Tangible-Equity of 0.10% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Takara Bio and its competitors. This is 98% below median its historical median of 5.81. According to the industry distribution chart, Takara Bio ranks #367 out of 1195 companies in the Biotechnology industry, placing it in the top 30.7%.
Is Takara Bio's Return-on-Tangible-Equity too high?
Takara Bio's current Return-on-Tangible-Equity of 0.10% is 98% below median its 10-year median of 5.81. Based on the distribution chart, Takara Bio ranks #367 out of 1195 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Takara Bio has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Takara Bio ranks #367 out of 1195 companies for Return-on-Tangible-Equity. This puts Takara Bio in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Takara Bio and its competitors. Takara Bio's current Return-on-Tangible-Equity is 0.10%, which is 98% below median its own 10-year median of 5.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Takara Bio (FRA:TF2) has a current Return-on-Tangible-Equity of 0.10%. The stock's GF Value™ is €4.47, compared to a current price of €5.95 — trading 33.1% above its estimated fair value. The current Return-on-Tangible-Equity is 0.10%, which is 98% below median its 10-year median of 5.81. Takara Bio's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current Return-on-Tangible-Equity is 0.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takara Bio (FRA:TF2) Overvalued in 2026?
Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued.
The current stock price of €5.95 is trading 33.1% above its estimated GF Value™ of €4.47.
Key valuation signals for FRA:TF2:
Return-on-Tangible-Equity: 0.10% (98% below median its 10-year median of 5.81)
GF Value™: €4.47 vs. price of €5.95 (33.1% above fair value)
No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
50GF Score
Get the complete analysis for FRA:TF2
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TF2 has been successfully added to your 
